Study flags need to monitor frailty risks with GLP-1 drugs for older adults

A large study suggests “potential signs of frailty” in older adults taking Eli Lilly’s GLP-1 obesity drug Zepbound, highlighting elevated risk of adverse outcomes in seniors. The findings raise monitoring concerns as Medicare expands access to GLP-1 therapies. Overall, the article is a cautionary read-through for GLP-1 uptake among Medicare beneficiaries rather than a reported efficacy withdrawal.

Analysis

A large study suggests “potential signs of frailty” in older adults taking Eli Lilly’s GLP-1 obesity drug Zepbound, highlighting elevated risk of adverse outcomes in seniors. The findings raise monitoring concerns as Medicare expands access to GLP-1 therapies. Overall, the article is a cautionary read-through for GLP-1 uptake among Medicare beneficiaries rather than a reported efficacy withdrawal.